Insights

Pfizer and BioNTech’s COVID-19 vaccine authorized by the FDA for adolescents

Parents are pleased, but the move won’t change much for the drug companies from a financial perspective.
The post Pfizer and BioNTech’s COVID-19 vaccine authorized by the FDA for adolescents appeared first on The Motley Fool Australia. –

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

health prffesional giving someone a vaccine

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

In a widely expected move, the Food and Drug Administration has expanded its emergency use authorization for Pfizer (NYSE: PFE) and BioNTech‘s (NASDAQ: BNTX) COVID-19 vaccine to include people as young as 12 years old.

The widened authorization for BNT162b2 was based on the ability of the vaccine to induce the production of COVID-19 antibodies; the levels of antibodies it generated in clinical trial participants ages 12 through 15 were at least as good as the antibody levels in participants in the 16-to-25 age range.

Those antibodies appear to protect patients from being infected by the coronavirus.

Measured starting one week after they received their second doses of BNT162b2, none of the 1,005 adolescents who were inoculated developed COVID-19. Among the 978 trial participants who received placebo shots, there were 16 cases of COVID-19. That equates to a finding of 100% protection, although the numbers in the study were relatively small.

The side effect profile for the adolescents was similar to that seen in those 16 and older. In both groups, people had more side effects after the second dose than the first dose.

Pfizer and BioNTech beat Moderna (NASDAQ: MRNA) to the finish line in terms of gaining FDA authorization for their vaccine to be administered to adolescents. However, BNT162b2’s period of exclusivity in that demographic, which presumably will only last for a couple of months, isn’t likely to be much of a financial advantage. Large sales contracts with the U.S. government are already in place for both mRNA vaccines, so opening the use of BNT162b2 to a wider age group won’t increase its sales. Until another vaccine is authorized for adolescents, some of Pfizer’s doses will be used for adolescents, and any supply tightening that might cause for the adult demographic will be filled by Moderna’s vaccine or Johnson & Johnson’s.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Brian Orelli, PhD has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends Johnson & Johnson and Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Pfizer and BioNTech’s COVID-19 vaccine authorized by the FDA for adolescents appeared first on The Motley Fool Australia.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Important Notice
Trade The US Market With ZERO Brokerage* + FREE Access To Trading Ideas & Value Analysis Tools. Click Here!